NEWARK, Calif.--(BUSINESS WIRE)-- AceLink Therapeutics, Inc., a clinical stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the quality of life of patients with inherited disorders of glycosphingolipid metabolism, today announced that Jerry Shen, Ph.D., Chief Executive Officer and Co-Founder of AceLink Therapeutics, will present at the World Orphan Drug Congress Conference being held in Washington D.C., from May 23-25, 2023.

Details of the presentation are as follows:

Title: Clinical-stage development of novel GCS inhibitors to treat lysosomal storage diseases
Presenter: Jerry Shen, Ph.D., Chief Executive Officer and Co-Founder of AceLink Therapeutics
Track: Pitch and Partner
Date and Time: Wednesday, May 24, 2023, 3:10 PM ET

About AceLink Therapeutics, Inc.

Founded in 2018, AceLink Therapeutics is a clinical stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs) to address significant unmet medical needs and improve the quality of life of patients with inherited disorders of glycosphingolipid metabolism. The company is developing a pipeline of breakthrough therapeutics including a phase 2-ready program for Fabry and Type 1 Gaucher disease. For more information, please visit www.acelinktherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230517005096/en/